Page 32 of 39 · 913 questions tagged clinical-trials.
Conditions: semaglutide · STEP 5. This is one of those things that everyone repeats and nobody derives. This matters practically, not just academically, because it…
Conditions: constipation · liraglutide · ESSENCE. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
I have three data points across nine months, which I hope is enough to see a trend. This is presented as though it settles something, and I am not convinced it does.…
The particulars: tirzepatide · minus 20 °C. Somebody stated this to me confidently and I would like to check it before repeating it. I would accept a well-reasoned…
The case in front of me: SURMOUNT-1 · tirzepatide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
Concretely: semaglutide · 4 °C. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and monographs without…
Stated plainly: SURPASS-3 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
I am asking about the pattern rather than about my own management, which is elsewhere. I understand the observation; what I do not understand is the mechanism behind…
Concretely: SURMOUNT-OSA · liraglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and monographs…
Setup, so nobody has to ask: 5 mg · mazdutide. I am trying to build something sustainable rather than something thorough that I will abandon. I have already decided…
Conditions: TRIUMPH-3 · dizziness. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change…
Conditions: survodutide · semaglutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can…
Numbers first: 8 mg · dulaglutide. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum viable…
Setup, so nobody has to ask: SURMOUNT-4 · mazdutide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…
The case in front of me: STEP 2 · 2 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
Stated plainly: STEP 2 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…
Stated plainly: retatrutide · PIONEER-1. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather hear…
Numbers first: mazdutide · SUSTAIN-6. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how…
What I am working with: dulaglutide · 2–8 °C. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched…
What I am working with: PIONEER-4 · dizziness. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Stated plainly: dulaglutide · TRIUMPH-3. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious. My background is…
Stated plainly: dulaglutide · mazdutide. Both of these get recommended confidently by different people, which suggests neither is obviously right. My constraints are…
Stated plainly: STEP 5 · 15 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including the method…
My records go back to the first dose with dates, so I can reconstruct the timeline exactly. I have read the primary source rather than the summary, which has left me…